

# Gerasimos Filippatos

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10891833/publications.pdf>

Version: 2024-02-01

383  
papers

124,532  
citations

668

122  
h-index

115

342  
g-index

388  
all docs

388  
docs citations

388  
times ranked

64443  
citing authors

#	ARTICLE	IF	CITATIONS
1	Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1014-1023.	0.7	50
2	Telomere length is independently associated with all-cause mortality in chronic heart failure. <i>Heart</i> , 2022, 108, 124-129.	2.9	5
3	Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by <scp>GLPâ€‘1 RA</scp> treatment: A subgroup analysis from the <scp>FIDELIOâ€‘DKD</scp> trial. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 125-134.	4.4	41
4	Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy. <i>Kidney International Reports</i> , 2022, 7, 36-45.	0.8	73
5	Impaired Endothelial Glycocalyx Predicts Adverse Outcome in Subjects Without Overt Cardiovascular Disease: a 6-Year Follow-up Study. <i>Journal of Cardiovascular Translational Research</i> , 2022, 15, 890-902.	2.4	13
6	Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. <i>European Heart Journal</i> , 2022, 43, 474-484.	2.2	341
7	Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 225-237.	6.1	89
8	Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 35-45.	11.4	29
9	Patiomer for the management of hyperkalaemia in patients receiving reninâ€‘angiotensinâ€‘aldosterone system inhibitors for heart failure: design and rationale of the <scp>DIAMOND</scp> trial. <i>European Journal of Heart Failure</i> , 2022, 24, 230-238.	7.1	32
10	Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory <i>post hoc</i> analyses from FIDELIO-DKD compared to reported CREDENCE results. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1261-1269.	0.7	32
11	Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial. <i>Circulation</i> , 2022, 145, 184-193.	1.6	106
12	Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial. <i>Circulation</i> , 2022, 145, 437-447.	1.6	86
13	Early benefit with empagliflozin in heart failure with preserved ejection fraction: <scp>insights from the EMPERORâ€‘Preserved trial</scp>. <i>European Journal of Heart Failure</i> , 2022, 24, 245-248.	7.1	26
14	Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from <scp>EMPERORâ€‘</scp>Reduced. <i>European Journal of Heart Failure</i> , 2022, 24, 708-715.	7.1	32
15	Regional differences in precipitating factors of hospitalization for acute heart failure: insights from the <scp>REPORTâ€‘HF</scp> registry. <i>European Journal of Heart Failure</i> , 2022, 24, 645-652.	7.1	18
16	Sodiumâ€‘glucose coâ€‘transporter 2 inhibitors as an early, firstâ€‘line therapy in patients with heart failure and reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2022, 24, 431-441.	7.1	67
17	Robustness of outcomes in trials evaluating sodiumâ€‘glucose coâ€‘transporter 2 inhibitors for heart failure. <i>ESC Heart Failure</i> , 2022, , .	3.1	4
18	Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. <i>Diabetes Care</i> , 2022, 45, e888-e897.	8.6	20

#	ARTICLE	IF	CITATIONS
19	A comprehensive characterization of acute heart failure with preserved versus mildly reduced versus reduced ejection fraction—insights from the <sc>ESCâ€HFA EORP</sc> Heart Failure Longâ€Term Registry. European Journal of Heart Failure, 2022, 24, 335-350.	7.1	49
20	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 2022, 24, 4-131.	7.1	820
21	Assessment of Proximal Tubular Function by Tubular Maximum Phosphate Reabsorption Capacity in Heart Failure. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 228-239.	4.5	4
22	Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. European Heart Journal, 2022, 43, 416-424.	2.2	144
23	Rising trends in Takotsubo syndrome during the COVID-19 pandemic: A single center experience. Hellenic Journal of Cardiology, 2022, , .	1.0	1
24	Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the <sc>FIDELIOâ€DKD</sc> trial. European Journal of Heart Failure, 2022, 24, 996-1005.	7.1	23
25	Influence of atrial fibrillation on efficacy and safety of omecamtiv mecarbil in heart failure: the GALACTIC-HF trial. European Heart Journal, 2022, 43, 2212-2220.	2.2	10
26	Mineralocorticoid Receptor Antagonists and Empagliflozin in Patients With Heartâ€Failure and Preserved Ejectionâ€Fraction. Journal of the American College of Cardiology, 2022, 79, 1129-1137.	2.8	36
27	Quality of life assessed six months after hospitalisation for acute heart failure: An analysis from <sc>REPORTâ€CHF</sc> (International Registry to assess <sc>mEdical</sc> Practice with) Tj ETQq1 1 0.784314 rgBT /Overlock 1 Failure. 2022, ...	7.1	12
28	Prognostic Implications of N-Terminal Proâ€B-Type Natriuretic Peptide and High-Sensitivity Cardiac Troponin T in EMPEROR-Preserved. JACC: Heart Failure, 2022, 10, 512-524.	4.1	20
29	Outcomes with empagliflozin in heart failure with preserved ejection fraction using <sc>DELIVER</sc>â€like endpoint definitions. European Journal of Heart Failure, 2022, 24, 1400-1405.	7.1	14
30	Biomarkers for the prediction of heart failure and cardiovascular events in patients with type 2 diabetes: a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2022, 24, 1162-1170.	7.1	13
31	Acetazolamide in Decompensated Heart Failure with Volume Overload trial (<sc>ADVOR</sc>): baseline characteristics. European Journal of Heart Failure, 2022, 24, 1601-1610.	7.1	18
32	Prevention of sudden death in heart failure with reduced ejection fraction: do we still needâ€An implantable cardioverterâ€defibrillator for primary prevention?. European Journal of Heart Failure, 2022, 24, 1460-1466.	7.1	12
33	Biomarkerâ€driven prognostic models in chronic heart failure with preserved ejection fraction: the <sc>EMPEROR</sc>â€Preserved trial. European Journal of Heart Failure, 2022, 24, 1869-1878.	7.1	21
34	Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial. European Heart Journal, 2022, 43, 3435-3446.	2.2	39
35	Empagliflozin Improves Outcomes inâ€Patients With Heartâ€Failure and Preserved Ejection Fraction Irrespective of Age. Journal of the American College of Cardiology, 2022, 80, 1-18.	2.8	21
36	Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction. Circulation, 2021, 143, 326-336.	1.6	222

#	ARTICLE	IF	CITATIONS
37	Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function. <i>Circulation</i> , 2021, 143, 310-321.	1.6	168
38	Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes. <i>Circulation</i> , 2021, 143, 540-552.	1.6	171
39	Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. <i>New England Journal of Medicine</i> , 2021, 384, 105-116.	27.0	381
40	Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status. <i>Circulation</i> , 2021, 143, 337-349.	1.6	217
41	Effects of a Novel Nitroxyl Donor in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 146-157.	4.1	17
42	2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). <i>European Heart Journal</i> , 2021, 42, 373-498.	2.2	5,583
43	Association of left ventricular ejection fraction with worsening renal function in patients with acute heart failure: insights from the RELAXAHF study. <i>European Journal of Heart Failure</i> , 2021, 23, 58-67.	7.1	10
44	Arrhythmias in cancer: rhythm is gonna get you!. <i>European Journal of Heart Failure</i> , 2021, 23, 154-156.	7.1	8
45	Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , 2021, 42, 671-680.	2.2	96
46	Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , 2021, 42, 1203-1212.	2.2	114
47	Sodium glucose co-transporter inhibitors and heart failure outcomes across different patient populations. <i>European Heart Journal</i> , 2021, 42, 4887-4890.	2.2	11
48	Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1397-1407.	2.8	105
49	Dipeptidyl peptidase 3, a marker of the antagonist pathway of the renin-angiotensin-aldosterone system in patients with heart failure. <i>European Journal of Heart Failure</i> , 2021, 23, 947-953.	7.1	9
50	Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1381-1392.	2.8	94
51	The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), and European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC. <i>European Heart Journal</i> , 2021, 42, 1254-1269.	2.2	78
52	Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. <i>European Journal of Heart Failure</i> , 2021, 23, 352-380.	7.1	630
53	Universal Definition and Classification of Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, 27, 387-413.	1.7	362
54	Global Differences in Burden and Treatment of Ischemic Heart Disease in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 349-359.	4.1	14

#	ARTICLE	IF	CITATIONS
55	Patient profiling in heart failure for tailoring medical therapy. A consensus document of the <scp>Heart Failure Association of the European Society of Cardiology</scp>. European Journal of Heart Failure, 2021, 23, 872-881.	7.1	160
56	Perceived risk profile and treatment optimization in heart failure: an analysis from BIOlogy Study to Tailored Treatment in chronic heart failure. Clinical Cardiology, 2021, 44, 780-788.	1.8	3
57	Neutrophil-to-lymphocyte ratio and outcomes in patients with new-onset or worsening heart failure with reduced and preserved ejection fraction. ESC Heart Failure, 2021, 8, 3168-3179.	3.1	33
58	Relation of Decongestion and Time to Diuretics to Biomarker Changes and Outcomes in Acute Heart Failure. American Journal of Cardiology, 2021, 147, 70-79.	1.6	7
59	Association between up-titration of medical therapy and total hospitalizations and mortality in patients with recent worsening heart failure across the ejection fraction spectrum. European Journal of Heart Failure, 2021, 23, 1170-1181.	7.1	11
60	Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. European Heart Journal, 2021, 42, 4442-4451.	2.2	38
61	Concentration-dependent clinical and prognostic importance of high-sensitivity cardiac troponin T in heart failure and a reduced ejection fraction and the influence of empagliflozin: the <scp>EMPEROR</scp>-Reduced trial. European Journal of Heart Failure, 2021, 23, 1529-1538.	7.1	30
62	Serum uric acid and outcomes in patients with chronic heart failure through the whole spectrum of ejection fraction phenotypes: Analysis of the ESC-EORP Heart Failure Long-Term (HF LT) Registry. European Journal of Internal Medicine, 2021, 89, 65-75.	2.2	18
63	Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes. Journal of the American College of Cardiology, 2021, 78, 142-152.	2.8	74
64	Sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction: reasons for optimism. European Journal of Heart Failure, 2021, 23, 1250-1255.	7.1	17
65	Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. New England Journal of Medicine, 2021, 385, 2252-2263.	27.0	599
66	Guidance on the management of left ventricular assist device <scp>(LVAD)</scp> supported patients for the non-<scp>LVAD</scp> specialist healthcare provider: executive summary. European Journal of Heart Failure, 2021, 23, 1597-1609.	7.1	20
67	Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved Trial. Circulation, 2021, 144, 1284-1294.	1.6	195
68	Empagliflozin and Major Renal Outcomes in Heart Failure. New England Journal of Medicine, 2021, 385, 1531-1533.	27.0	78
69	Empagliflozin in Heart Failure with a Preserved Ejection Fraction. New England Journal of Medicine, 2021, 385, 1451-1461.	27.0	2,143
70	Novel biomarker-driven prognostic models to predict morbidity and mortality in chronic heart failure: the EMPEROR-Reduced trial. European Heart Journal, 2021, 42, 4455-4464.	2.2	33
71	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2021, 42, 3599-3726.	2.2	5,558
72	Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the <scp>EMPEROR-Preserved</scp> trial. European Journal of Heart Failure, 2021, 23, 1798-1799.	7.1	21

#	ARTICLE	IF	CITATIONS
73	Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial. Journal of the American College of Cardiology, 2021, 78, 1321-1332.	2.8	55
74	Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure. Journal of the American College of Cardiology, 2021, 78, 1337-1348.	2.8	52
75	HFA of the ESC Position paper on the management of LVAD supported patients for the non LVAD specialist healthcare provider Part 1: Introduction and at the non hospital settings in the community. ESC Heart Failure, 2021, 8, 4394-4408.	3.1	5
76	Response by Filippatos et al to Letter Regarding Article, "Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes". Circulation, 2021, 144, e202-e203.	1.6	7
77	Amended <sc>STRONG</sc> study design. European Journal of Heart Failure, 2021, 23, 1981-1982.	7.1	8
78	HFA of the ESC position paper on the management of LVAD supported patients for the non LVAD specialist healthcare provider Part 3: at the hospital and discharge. ESC Heart Failure, 2021, 8, 4425-4443.	3.1	10
79	Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. European Heart Journal, 2021, 42, 700-710.	2.2	117
80	The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study. European Heart Journal, 2021, 42, 3011-3020.	2.2	71
81	Cancer and Takotsubo syndrome: from rarity to clinical practice. ESC Heart Failure, 2021, 8, 4365-4369.	3.1	12
82	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal, 2020, 41, 255-323.	2.2	2,811
83	Plasma proteomic approach in patients with heart failure: insights into pathogenesis of disease progression and potential novel treatment targets. European Journal of Heart Failure, 2020, 22, 70-80.	7.1	28
84	Global Differences in Characteristics, Precipitants, and Initial Management of Patients Presenting With Acute Heart Failure. JAMA Cardiology, 2020, 5, 401.	6.1	51
85	Sex and age related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Long Term Registry. European Journal of Heart Failure, 2020, 22, 92-102.	7.1	81
86	Effects of serelaxin in patients admitted for acute heart failure: a meta-analysis. European Journal of Heart Failure, 2020, 22, 315-329.	7.1	24
87	European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure. European Journal of Heart Failure, 2020, 22, 196-213.	7.1	131
88	Imaging in patients with suspected acute heart failure: timeline approach position statement on behalf of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2020, 22, 181-195.	7.1	47
89	Cardiovascular and non-cardiovascular death distinction: the utility of troponin beyond N-terminal pro-B-type natriuretic peptide. Findings from the BIOSTAT-CHF study. European Journal of Heart Failure, 2020, 22, 81-89.	7.1	15
90	Distribution, infrastructure, and expertise of heart failure and cardio-oncology clinics in a developing network: temporal evolution and challenges during the coronavirus disease 2019 pandemic. ESC Heart Failure, 2020, 7, 3408-3413.	3.1	6

#	ARTICLE	IF	CITATIONS
91	Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: <scp>GALACTICâ€HF</scp> baseline characteristics and comparison with contemporary clinical trials. European Journal of Heart Failure, 2020, 22, 2160-2171.	7.1	47
92	Economic implications of adding a novel algorithm to optimize cardiac resynchronization therapy: rationale and design of economic analysis for the AdaptResponse trial. Journal of Medical Economics, 2020, 23, 1401-1408.	2.1	1
93	Heart failure in Greece: The Hellenic National Nutrition and Health Survey (HNNHS). Hellenic Journal of Cardiology, 2020, 62, 315-317.	1.0	2
94	Conduct of Clinical Trials in the Era of COVID-19. Journal of the American College of Cardiology, 2020, 76, 2368-2378.	2.8	35
95	Design of a prospective patientâ€level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure. European Journal of Heart Failure, 2020, 22, 2393-2398.	7.1	19
96	Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. Lancet, The, 2020, 396, 1895-1904.	13.7	425
97	Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPERORâ€Preserved trial. European Journal of Heart Failure, 2020, 22, 2383-2392.	7.1	93
98	Loop Diuretic Prescription and 30-Dayâ€Outcomes in Older Patients Withâ€Heartâ€Failure. Journal of the American College of Cardiology, 2020, 76, 669-679.	2.8	41
99	Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. New England Journal of Medicine, 2020, 383, 2219-2229.	27.0	1,148
100	Ten lessons from the <scp>EMPERORâ€Reduced</scp> trial. European Journal of Heart Failure, 2020, 22, 1991-1993.	7.1	6
101	Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. New England Journal of Medicine, 2020, 383, 1413-1424.	27.0	2,821
102	SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet, The, 2020, 396, 819-829.	13.7	816
103	Totality of evidence in trials of sodiumâ€glucose co-transporter-2 inhibitors in the patients with heart failure with reduced ejection fraction: implications for clinical practice. European Heart Journal, 2020, 41, 3398-3401.	2.2	20
104	A Clinical Tool to Predict Low Serum Selenium in Patients with Worsening Heart Failure. Nutrients, 2020, 12, 2541.	4.1	16
105	Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of reninâ€angiotensinâ€aldosterone inhibitors. European Heart Journal, 2020, 41, 1810-1817.	2.2	381
106	Epidemiology, pathophysiology and contemporary management of cardiogenic shockâ€Aâ€ position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2020, 22, 1315-1341.	7.1	244
107	Sodiumâ€glucose coâ€transporter 2 inhibitors: â€a tale of two sistersâ€™, diabetes and heart failure. European Journal of Heart Failure, 2020, 22, 1259-1262.	7.1	2
108	Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Heart Journal, 2020, 41, 2109-2117.	2.2	65



#	ARTICLE	IF	CITATIONS
109	Heart failure in the course of a pandemic. <i>European Journal of Heart Failure</i> , 2020, 22, 1755-1758.	7.1	5
110	Heart Failure Association of the European Society of Cardiology Quality of Care Centres Programme: design and accreditation document. <i>European Journal of Heart Failure</i> , 2020, 22, 763-774.	7.1	24
111	How to diagnose heart failure with preserved ejection fraction: the HFAâ€PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Journal of Heart Failure</i> , 2020, 22, 391-412.	7.1	193
112	Cancer treatment and atrial fibrillation: use of pharmacovigilance databases to detect cardiotoxicity. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 7, 321-323.	3.0	9
113	Is heart failure misdiagnosed in hospitalized patients with preserved ejection fraction? From the European Society of Cardiology â€Heart Failure Association EURObservational Research Programme Heart Failure Longâ€Term Registry. <i>ESC Heart Failure</i> , 2020, 7, 2098-2112.	3.1	23
114	How to develop a national heart failure clinics network: a consensus document of the Hellenic Heart Failure Association. <i>ESC Heart Failure</i> , 2020, 7, 15-25.	3.1	10
115	Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial. <i>Journal of Cardiac Failure</i> , 2020, 26, 429-437.	1.7	46
116	Post-discharge prognosis of patients admitted to hospital for heart failure by world region, and national level of income and income disparity (REPORT-HF): a cohort study. <i>The Lancet Global Health</i> , 2020, 8, e411-e422.	6.3	104
117	Treatment with 24â€hour istaroxime infusion in patients hospitalised for acute heart failure: a randomised, placeboâ€controlled trial. <i>European Journal of Heart Failure</i> , 2020, 22, 1684-1693.	7.1	48
118	Geographical differences in heart failure characteristics and treatment across Europe: results from the BIOSTAT-CHF study. <i>Clinical Research in Cardiology</i> , 2020, 109, 967-977.	3.3	7
119	Acute coronary syndromes and acute heart failure: a diagnostic dilemma and highâ€risk combination. A statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020, 22, 1298-1314.	7.1	50
120	Prevalence of risk of thrombosis and of bleeding and antithrombotic treatment in patients with heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 906-910.	7.1	5
121	Unravelling the interplay between hyperkalaemia, reninâ€angiotensinâ€aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESCâ€HFAâ€EORP Heart Failure Longâ€Term Registry. <i>European Journal of Heart Failure</i> , 2020, 22, 1378-1389.	7.1	83
122	Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESCâ€EORP Heart Failure Longâ€Term Registry. <i>European Journal of Heart Failure</i> , 2020, 22, 1424-1437.	7.1	36
123	Megaâ€trials in heart failure: effects of dilution in examination of new therapies. <i>European Journal of Heart Failure</i> , 2020, 22, 1698-1707.	7.1	11
124	Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and metaâ€analysis. <i>ESC Heart Failure</i> , 2020, 7, 3298-3309.	3.1	76
125	Cardioâ€oncology services during the <scp>COVID</scp>â€19 pandemic: practical considerations and challenges. <i>European Journal of Heart Failure</i> , 2020, 22, 929-932.	7.1	4
126	Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction. <i>Clinical Research in Cardiology</i> , 2020, 109, 1048-1059.	3.3	20



#	ARTICLE	IF	CITATIONS
127	Heart failure guidelines implementation: Lifting barriers with registries and networks. <i>Anatolian Journal of Cardiology</i> , 2020, 24, 41-42.	0.9	2
128	Fourth universal definition of myocardial infarction (2018). <i>European Heart Journal</i> , 2019, 40, 237-269.	2.2	2,687
129	Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP and GDF-15, of Heart Failure therapies (STRONG-HF): rationale and design for a multicentre, randomized, parallel-group study. <i>European Journal of Heart Failure</i> , 2019, 21, 1459-1467.	7.1	34
130	Effects of Seralaxin in Patients with Acute Heart Failure. <i>New England Journal of Medicine</i> , 2019, 381, 716-726.	27.0	174
131	Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial. <i>European Journal of Heart Failure</i> , 2019, 21, 1270-1278.	7.1	155
132	Hepatorenal dysfunction identifies high-risk patients with acute heart failure: insights from the RELAX-AHF trial. <i>ESC Heart Failure</i> , 2019, 6, 1188-1198.	3.1	22
133	A look back: the quest for thrombosis in heart failure continues after COMMANDER HF. <i>Cardiovascular Research</i> , 2019, 115, e140-e142.	3.8	4
134	Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial. <i>American Journal of Nephrology</i> , 2019, 50, 345-356.	3.1	127
135	Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial. <i>American Journal of Nephrology</i> , 2019, 50, 333-344.	3.1	112
136	How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2019, 40, 3297-3317.	2.2	944
137	Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2019, 21, 1169-1186.	7.1	490
138	Rationale and design of the EMPERIAL-Preserved and EMPERIAL-Reduced trials of empagliflozin in patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2019, 21, 932-942.	7.1	40
139	Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. <i>European Journal of Heart Failure</i> , 2019, 21, 715-731.	7.1	446
140	Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world. <i>European Journal of Heart Failure</i> , 2019, 21, 1383-1397.	7.1	35
141	Acute heart failure congestion and perfusion status: Impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2019, 21, 1338-1352.	7.1	170
142	Effect of ferric carboxymaltose on calculated plasma volume status and clinical congestion: a FAIR-HF substudy. <i>ESC Heart Failure</i> , 2019, 6, 621-628.	3.1	19
143	Utility of Urine Neutrophil Gelatinase-Associated Lipocalin for Worsening Renal Function during Hospitalization for Acute Heart Failure: Primary Findings of the Urine N-gal Acute Kidney Injury N-gal Evaluation of Symptomatic Heart Failure Study (AKINESIS). <i>Journal of Cardiac Failure</i> , 2019, 25, 654-665.	1.7	23
144	Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 95, 1304-1317.	5.2	232

#	ARTICLE	IF	CITATIONS
145	Rationale and design of the AFFIRMâ€”AHF trial: a randomised, doubleâ€”blind, placeboâ€”controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in ironâ€”deficient patients admitted for acute heart failure. <i>European Journal of Heart Failure</i> , 2019, 21, 1651-1658.	7.1	42
146	Inhibition of the renin-angiotensin system in the cardiorenal syndrome with anaemia. <i>Journal of Hypertension</i> , 2019, 37, 2145-2153.	0.5	3
147	The use of diuretics in heart failure with congestion â€” a position statement from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2019, 21, 137-155.	7.1	605
148	Atrial Fibrillation in Cancer. <i>Current Clinical Pathology</i> , 2019, , 113-121.	0.0	0
149	Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge. <i>European Journal of Heart Failure</i> , 2018, 20, 879-887.	7.1	138
150	CRT Survey II: a European Society of Cardiology survey of cardiac resynchronisation therapy in 11 088 patientsâ€”who is doing what to whom and how?. <i>European Journal of Heart Failure</i> , 2018, 20, 1039-1051.	7.1	107
151	Overview of mitral regurgitation in Europe: results from the European Registry of mitral regurgitation (EuMiClip). <i>European Heart Journal Cardiovascular Imaging</i> , 2018, 19, 503-507.	1.2	42
152	Anthracyclineâ€”induced cardiomyopathy: secrets and lies. <i>European Journal of Heart Failure</i> , 2018, 20, 907-909.	7.1	24
153	Vaccination in Heart Failure: An Approach to Improve Outcomes. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2018, 71, 697-699.	0.6	2
154	Renin inhibition in heart failure and diabetes: the real story. <i>European Journal of Heart Failure</i> , 2018, 20, 149-151.	7.1	7
155	Evaluation of an individualized dose titration regimen of patiomer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease. <i>ESC Heart Failure</i> , 2018, 5, 257-266.	3.1	50
156	Biomarker-Guided Versus Guideline-Based Treatment of Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2018, 71, 386-398.	2.8	35
157	Heart and brain interaction in patients with heart failure: overview and proposal for a taxonomy. A position paper from the Study Group on Heart and Brain Interaction of the Heart Failure Association. <i>European Journal of Heart Failure</i> , 2018, 20, 199-215.	7.1	128
158	Site enrollment rate, outcomes, and study drug effects in a multicenter trial. Results from RELAX-AHF. <i>International Journal of Cardiology</i> , 2018, 253, 91-96.	1.7	2
159	Potassium and the use of reninâ€”angiotensinâ€”aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTATâ€”CHF. <i>European Journal of Heart Failure</i> , 2018, 20, 923-930.	7.1	57
160	Fibroblast growth factor 23 is related to profiles indicating volume overload, poor therapy optimization and prognosis in patients with new-onset and worsening heart failure. <i>International Journal of Cardiology</i> , 2018, 253, 84-90.	1.7	55
161	Indications and practical approach to non-invasive ventilation in acute heart failure. <i>European Heart Journal</i> , 2018, 39, 17-25.	2.2	111
162	Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 180-188.	3.0	113

#	ARTICLE	IF	CITATIONS
163	Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis. <i>European Journal of Heart Failure</i> , 2018, 20, 125-133.	7.1	317
164	Relationship between baseline systolic blood pressure and long-term outcomes in acute heart failure patients treated with TRV027: an exploratory subgroup analysis of BLAST-AHF. <i>Clinical Research in Cardiology</i> , 2018, 107, 170-181.	3.3	27
165	Long-term safety of intravenous cardiovascular agents in acute heart failure: results from the European Society of Cardiology Heart Failure Long-term Registry. <i>European Journal of Heart Failure</i> , 2018, 20, 332-341.	7.1	69
166	Coronary angiography in worsening heart failure: determinants, findings and prognostic implications. <i>Heart</i> , 2018, 104, 606-613.	2.9	16
167	Using matrix assisted laser desorption ionisation mass spectrometry (MALDI-MS) profiling in order to predict clinical outcomes of patients with heart failure. <i>Clinical Proteomics</i> , 2018, 15, 35.	2.1	6
168	Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology. <i>European Heart Journal</i> , 2018, 39, 4243-4254.	2.2	171
169	Rationale and design of the ADVOR (Acetazolamide in Decompensated Heart Failure with Volume) Tj ETQq1 1 0.784314 rgBT/Overlook	7.1	73
170	Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14%964 patients in the European Society of Cardiology Heart Failure Long-Term Registry. <i>European Heart Journal</i> , 2018, 39, 4277-4284.	2.2	189
171	How to build a cardio-oncology service?. <i>European Journal of Heart Failure</i> , 2018, 20, 1732-1734.	7.1	27
172	Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2018, 20, 1505-1535.	7.1	555
173	La vacunación en la insuficiencia cardiaca: una estrategia que mejora el pronóstico. <i>Revista Espanola De Cardiologia</i> , 2018, 71, 697-699.	1.2	5
174	Waist-to-hip ratio and mortality in heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 1269-1277.	7.1	85
175	Rationale and design of a multicentre, randomized, placebo-controlled trial of mirabegron, a Beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease Beta3-left ventricular hypertrophy (Beta3-LVH). <i>ESC Heart Failure</i> , 2018, 5, 830-841.	3.1	29
176	Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial. <i>Circulation: Heart Failure</i> , 2018, 11, e004962.	3.9	117
177	Identifying Pathophysiological Mechanisms in Heart Failure With Reduced Versus Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1081-1090.	2.8	199
178	Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction. <i>European Heart Journal</i> , 2018, 39, 3867-3875.	2.2	47
179	A multimarker multi-time point-based risk stratification strategy in acute heart failure: results from the RELAX-AHF trial. <i>European Journal of Heart Failure</i> , 2017, 19, 1001-1010.	7.1	81
180	Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial. <i>Clinical Research in Cardiology</i> , 2017, 106, 444-456.	3.3	8

#	ARTICLE	IF	CITATIONS
181	Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure. <i>European Journal of Heart Failure</i> , 2017, 19, 627-634.	7.1	183
182	Association Between Diabetes and 1-Year Adverse Clinical Outcomes in a Multinational Cohort of Ambulatory Patients With Chronic Heart Failure: Results From the ESC-HFA Heart Failure Long-Term Registry. <i>Diabetes Care</i> , 2017, 40, 671-678.	8.6	103
183	Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure. <i>New England Journal of Medicine</i> , 2017, 376, 1956-1964.	27.0	257
184	Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the <scp>ESC</scp> Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2017, 19, 1242-1254.	7.1	339
185	Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study. <i>European Journal of Heart Failure</i> , 2017, 19, 800-809.	7.1	104
186	Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF). <i>European Heart Journal</i> , 2017, 38, 2364-2373.	2.2	102
187	Patient-reported outcomes in the <scp>SOLuble</scp> guanylate Cyclase <scp>stimulator</scp> in <scp>heart failure patients</scp> with <scp>PRESERVED</scp> ejection fraction (<scp>SOCRATES-PRESERVED</scp>) study. <i>European Journal of Heart Failure</i> , 2017, 19, 782-791.	7.1	84
188	Effects of serelaxin on the outcome of patients with or without substantial peripheral edema: A subgroup analysis from the RELAX-AHF trial. <i>American Heart Journal</i> , 2017, 190, 113-122.	2.7	10
189	Understanding worsening heart failure as a therapeutic target: another step forward?. <i>European Journal of Heart Failure</i> , 2017, 19, 996-1000.	7.1	1
190	How to Use Beta-Blockers in Heart Failure—With Reduced Ejection Fraction and Atrial Fibrillation —. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2897-2900.	2.8	10
191	Surrogate endpoints in heart failure: (once again) use with caution. <i>European Journal of Heart Failure</i> , 2017, 19, 563-565.	7.1	0
192	Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOLuble guanylate Cyclase stimulator in heart failure patients with PRESERVED EF (SOCRATES-PRESERVED) study. <i>European Heart Journal</i> , 2017, 38, 1119-1127.	2.2	285
193	Day vs night: Does time of presentation matter in acute heart failure? A secondary analysis from the RELAX-AHF trial. <i>American Heart Journal</i> , 2017, 187, 62-69.	2.7	9
194	Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2017, 19, 1574-1585.	7.1	568
195	Mitochondrial function as a therapeutic target in heart failure. <i>Nature Reviews Cardiology</i> , 2017, 14, 238-250.	13.7	525
196	Circulating Erythrocyte Microparticles and the Biochemical Extent of Myocardial Injury in ST Elevation Myocardial Infarction. <i>Cardiology</i> , 2017, 136, 15-20.	1.4	9
197	The PCSK9-LDL Receptor Axis and Outcomes in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2128-2136.	2.8	43
198	Contemporary Epidemiology, Management, and Outcomes of Patients Hospitalized for Heart Failure in China: Results From the China Heart Failure (China-HF) Registry. <i>Journal of Cardiac Failure</i> , 2017, 23, 868-875.	1.7	159

#	ARTICLE	IF	CITATIONS
199	The potential role and rationale for treatment of heart failure with sodium-glucose cotransporter 2 inhibitors. <i>European Journal of Heart Failure</i> , 2017, 19, 1390-1400.	7.1	139
200	Rationale and design of the AdaptResponse trial: a prospective randomized study of cardiac resynchronization therapy with preferential adaptive left ventricular-only pacing. <i>European Journal of Heart Failure</i> , 2017, 19, 950-957.	7.1	33
201	Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure. <i>JAMA Cardiology</i> , 2017, 2, 1025.	6.1	280
202	In-hospital and 1-year mortality associated with diabetes in patients with acute heart failure: results from the ESC-HF Long-Term Registry. <i>European Journal of Heart Failure</i> , 2017, 19, 54-65.	7.1	150
203	Sex differences in early dyspnea relief between men and women hospitalized for acute heart failure: insights from the RELAX-AHF study. <i>Clinical Research in Cardiology</i> , 2017, 106, 280-292.	3.3	17
204	Rationale for and design of the TRUE-AHF trial: the effects of ularitide on the short-term clinical course and long-term mortality of patients with acute heart failure. <i>European Journal of Heart Failure</i> , 2017, 19, 673-681.	7.1	31
205	Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF. <i>European Journal of Heart Failure</i> , 2017, 19, 1284-1293.	7.1	79
206	Immunosenescence in patients with chronic systolic heart failure. <i>Journal of Cardiovascular Medicine</i> , 2016, 17, 624-630.	1.5	12
207	European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. <i>European Journal of Heart Failure</i> , 2016, 18, 613-625.	7.1	538
208	Updated Clinical Practice Guidelines on Heart Failure: An International Alignment. <i>Journal of Cardiac Failure</i> , 2016, 22, 670-671.	1.7	1
209	Body surface area as a prognostic marker in chronic heart failure patients: results from the Heart Failure Registry of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2016, 18, 859-868.	7.1	36
210	Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials. <i>European Journal of Heart Failure</i> , 2016, 18, 786-795.	7.1	270
211	Use of High-Sensitivity Troponin T to Identify Patients With Acute Heart Failure at Lower Risk for Adverse Outcomes. <i>JACC: Heart Failure</i> , 2016, 4, 591-599.	4.1	49
212	Relation of Longitudinal Changes in Quality of Life Assessments to Changes in Functional Capacity in Patients With Heart Failure With and Without Anemia. <i>American Journal of Cardiology</i> , 2016, 117, 1482-1487.	1.6	12
213	Updated Clinical Practice Guidelines on Heart Failure: An International Alignment. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1474-1475.	2.8	3
214	Updated Clinical Practice Guidelines on Heart Failure: An International Alignment. <i>Circulation</i> , 2016, 134, e280-1.	1.6	7
215	2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1476-1488.	2.8	549
216	Updated Clinical Practice Guidelines on Heart Failure: An International Alignment. <i>European Heart Journal</i> , 2016, 37, 2096-2096.	2.2	8

#	ARTICLE	IF	CITATIONS
217	EACVI appropriateness criteria for the use of cardiovascular imaging in heart failure derived from European National Imaging Societies voting. European Heart Journal Cardiovascular Imaging, 2016, 17, 711-721.	1.2	22
218	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Journal of Cardio-thoracic Surgery, 2016, 50, e1-e88.	1.4	754
219	Reframing the association and significance of comorbidities in heart failure. European Journal of Heart Failure, 2016, 18, 744-758.	7.1	169
220	Current state of knowledge on Takotsubo syndrome: a Position Statement from the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2016, 18, 8-27.	7.1	835
221	Contemporary management of acute right ventricular failure: a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology. European Journal of Heart Failure, 2016, 18, 226-241.	7.1	455
222	Updated Clinical Practice Guidelines on Heart Failure: An International Alignment. European Journal of Heart Failure, 2016, 18, 976-976.	7.1	1
223	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal, 2016, 37, 2893-2962.	2.2	5,689
224	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace, 2016, 18, 1609-1678.	1.7	3,523
225	Heart failure and kidney dysfunction: epidemiology, mechanisms and management. Nature Reviews Nephrology, 2016, 12, 610-623.	9.6	422
226	Structured discharge instructions for hospitalized heart failure patients to improve guideline implementation and patient outcomes. International Journal of Cardiology, 2016, 220, 143-145.	1.7	3
227	Neutrophil Gelatinase-Associated Lipocalin for Acute Kidney Injury During Acute Heart Failure Hospitalizations. Journal of the American College of Cardiology, 2016, 68, 1420-1431.	2.8	85
228	A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. European Heart Journal, 2016, 37, 2105-2114.	2.2	274
229	Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure. Circulation: Heart Failure, 2016, 9, .	3.9	51
230	Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside. Handbook of Experimental Pharmacology, 2016, 243, 271-305.	1.8	102
231	Heart Failure Association of the European Society of Cardiology heart failure nurse curriculum. European Journal of Heart Failure, 2016, 18, 736-743.	7.1	61
232	Natriuretic peptides revisited. Journal of Cardiovascular Medicine, 2016, 17, 840-842.	1.5	2
233	A systems Biology Study to Tailored Treatment in Chronic Heart Failure: rationale, design, and baseline characteristics of BIOSTAT-CHF. European Journal of Heart Failure, 2016, 18, 716-726.	7.1	149
234	Heart failure specialization in Europe. European Journal of Heart Failure, 2016, 18, 347-349.	7.1	9



#	ARTICLE	IF	CITATIONS
235	Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF. Clinical Research in Cardiology, 2016, 105, 727-737.	3.3	16
236	Recommendations on pre-hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. European Journal of Heart Failure, 2015, 17, 544-558.	7.1	315
237	Maintenance of serum potassium with sodium zirconium cyclosilicate (<sc>ZS</sc>) in heart failure patients: results from a phase 3 randomized, double-blind, placebo-controlled trial. European Journal of Heart Failure, 2015, 17, 1050-1056.	7.1	143
238	Growth differentiation factor 15 (<sc>GDF</sc>-15) in patients admitted for acute heart failure: results from the <sc>RELAX-AHF</sc> study. European Journal of Heart Failure, 2015, 17, 1133-1143.	7.1	86
239	Serial high sensitivity cardiac troponin T measurement in acute heart failure: insights from the <sc>RELAX-AHF</sc> study. European Journal of Heart Failure, 2015, 17, 1262-1270.	7.1	110
240	In-hospital worsening heart failure. European Journal of Heart Failure, 2015, 17, 1104-1113.	7.1	60
241	Overcoming the ethnic differences in patients hospitalized for heart failure: is there a need for international harmonization of clinical practice guidelines?. European Journal of Heart Failure, 2015, 17, 755-757.	7.1	5
242	B-type natriuretic peptide vs. cardiac risk scores for prediction of outcome following major orthopedic surgery. Journal of Cardiovascular Medicine, 2015, 16, 465-471.	1.5	11
243	Pulmonary Oedema—Therapeutic Targets. Cardiac Failure Review, 2015, 1, 38.	3.0	12
244	EACVI/HFA Cardiac Oncology Toxicity Registry in breast cancer patients: rationale, study design, and methodology (EACVI/HFA COT Registry)—EURObservational Research Program of the European Society of Cardiology. European Heart Journal Cardiovascular Imaging, 2015, 16, 466-470.	1.2	35
245	Recommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine — short version. European Heart Journal, 2015, 36, 1958-1966.	2.2	105
246	European Cardiac Resynchronization Therapy Survey II: rationale and design. Europace, 2015, 17, 137-141.	1.7	22
247	Heart Failure Therapeutics on the Basis of a Biased Ligand of the Angiotensin-2 Type 1 Receptor. JACC: Heart Failure, 2015, 3, 193-201.	4.1	68
248	Acute Heart Failure: Epidemiology, Risk Factors, and Prevention. Revista Espanola De Cardiologia (English Ed ), 2015, 68, 245-248.	0.6	64
249	Comparative evaluation of Acute Physiology and Chronic Health Evaluation II and Sequential Organ Failure Assessment scoring systems in patients admitted to the cardiac intensive care unit. Journal of Critical Care, 2015, 30, 752-757.	2.2	20
250	Clinical Trial Design Principles and Endpoint Definitions for Transcatheter Mitral Valve Repair and Replacement: Part 1: Clinical Trial Design Principles. Journal of the American College of Cardiology, 2015, 66, 278-307.	2.8	191
251	Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 1: clinical trial design principles. European Heart Journal, 2015, 36, 1851-1877.	2.2	37
252	Clinical trial design principles and endpoint definitions for transcatheter mitral valve repair and replacement: part 2: endpoint definitions. European Heart Journal, 2015, 36, 1878-1891.	2.2	133

#	ARTICLE	IF	CITATIONS
253	The impact of intravenous ferric carboxymaltose on renal function: an analysis of the <sc>FAIR&HF</sc> study. European Journal of Heart Failure, 2015, 17, 329-339.	7.1	92
254	International REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure (REPORT&HF): rationale for and design of a global registry. European Journal of Heart Failure, 2015, 17, 527-533.	7.1	52
255	A prospective comparison of alginate-hydrogel with standard medical therapy to determine impact on functional capacity and clinical outcomes in patients with advanced heart failure (AUGMENT-HF trial). European Heart Journal, 2015, 36, 2297-2309.	2.2	137
256	Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study&HF (ARTS&HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease. European Journal of Heart Failure, 2015, 17, 224-232.	7.1	74
257	Usefulness of Colchicine to Reduce Perioperative Myocardial Damage in Patients Who Underwent On-Pump Coronary Artery Bypass Grafting. American Journal of Cardiology, 2015, 115, 1376-1381.	1.6	38
258	Drug therapy for patients with systolic heart failure after the PARADIGM-HF trial: in need of a new paradigm of LCZ696 implementation in clinical practice. BMC Medicine, 2015, 13, 35.	5.5	23
259	Clinical trials in hospitalized heart failure patients: targeting interventions to optimal phenotypic subpopulations. Heart Failure Reviews, 2015, 20, 393-400.	3.9	3
260	Worsening Heart Failure Following Admission for Acute Heart Failure. JACC: Heart Failure, 2015, 3, 395-403.	4.1	44
261	Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies. European Heart Journal, 2015, 36, 715-723.	2.2	69
262	In-hospital management of acute heart failure: Practical recommendations and future perspectives. International Journal of Cardiology, 2015, 201, 231-236.	1.7	31
263	Anti-Inflammatory Treatment With Colchicine in Acute Myocardial Infarction. Circulation, 2015, 132, 1395-1403.	1.6	208
264	Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction. JAMA - Journal of the American Medical Association, 2015, 314, 2251.	7.4	288
265	Determinants of the direct cost of heart failure hospitalization in a public tertiary hospital. International Journal of Cardiology, 2015, 180, 46-49.	1.7	35
266	Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. European Heart Journal, 2015, 36, 657-668.	2.2	902
267	Moving Towards a Novel Paradigm in Drug Development for Worsening Heart Failure: The T1 Model (Mechanistic Translational Phase). , 2015, , 583-593.		0
268	Iron deficiency defined as depleted iron stores accompanied by unmet cellular iron requirements identifies patients at the highest risk of death after an episode of acute heart failure. European Heart Journal, 2014, 35, 2468-2476.	2.2	179
269	Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial. European Heart Journal, 2014, 35, 1041-1050.	2.2	90
270	Rationale and design of the <sc>SOLuble</sc> guanylate Cyclase <sc>stimulatoR</sc> in <sc>heArT failurE</sc> Studies (<sc>SOCRATES</sc>). European Journal of Heart Failure, 2014, 16, 1026-1038.	7.1	119

#	ARTICLE	IF	CITATIONS
271	Heart failure: preventing disease and death worldwide. ESC Heart Failure, 2014, 1, 4-25.	3.1	921
272	Heart Failure Association of the <scp>European Society of Cardiology</scp> Specialist Heart Failure Curriculum. European Journal of Heart Failure, 2014, 16, 151-162.	7.1	52
273	Rationale and design of the CONFIRMâ€CHF study: a doubleâ€blind, randomized, placeboâ€controlled study to assess the effects of intravenous ferric carboxymaltose on functional capacity in patients with chronic heart failure and iron deficiency. ESC Heart Failure, 2014, 1, 52-58.	3.1	38
274	Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcomeâ€”an analysis from <scp>RELAXâ€AHF</scp>. European Journal of Heart Failure, 2014, 16, 1230-1240.	7.1	134
275	Insights Into Onco-Cardiology. Journal of the American College of Cardiology, 2014, 63, 945-953.	2.8	295
276	Renal dysfunction and heart failure: things are seldom what they seem. European Heart Journal, 2014, 35, 416-418.	2.2	58
277	Developing Therapies for Heart Failure Withâ€Preservedâ€Ejection Fraction. JACC: Heart Failure, 2014, 2, 97-112.	4.1	267
278	Cardiopulmonary exercise testing in systolic heart failure in 2014: the evolving prognostic role. European Journal of Heart Failure, 2014, 16, 929-941.	7.1	83
279	2014 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal, 2014, 35, 2541-2619.	2.2	4,141
280	Effect of Serelaxin on Mode of Death inâ€Acute Heart Failure. Journal of the American College of Cardiology, 2014, 64, 1591-1598.	2.8	56
281	Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis. BMJ, The, 2014, 348, g3859-g3859.	6.0	291
282	Efficacy and safety of high dose versus low dose furosemide with or without dopamine infusion: The Dopamine in Acute Decompensated Heart Failure II (DAD-HF II) Trial. International Journal of Cardiology, 2014, 172, 115-121.	1.7	96
283	Differences in clinical characteristics, management and short-term outcome between acute heart failure patients chronic obstructive pulmonary disease and those without this co-morbidity. Clinical Research in Cardiology, 2014, 103, 733-741.	3.3	32
284	Temporal trends in epidemiology, clinical presentation and management of acute heart failure: results from the Greek cohorts of the Acute Heart Failure Global Registry of Standard Treatment and the European Society of Cardiology-Heart Failure pilot survey. European Heart Journal: Acute Cardiovascular Care, 2014, ., 204887261452701.	1.0	20
285	Improving care for patients with acute heart failure: before, during and after hospitalization. ESC Heart Failure, 2014, 1, 110-145.	3.1	222
286	Determinants of quality of life of patients with heart failure and iron deficiency treated with ferric carboxymaltose: FAIR-HF sub-analysis. International Journal of Cardiology, 2013, 168, 3878-3883.	1.7	30
287	Functional electrical stimulation of peripheral muscles improves endothelial function and clinical and emotional status in heart failure patients with preserved left ventricular ejection fraction. American Heart Journal, 2013, 166, 760-767.	2.7	45
288	Organization of heart failure management in European Society of Cardiology member countries: survey of the Heart Failure Association of the European Society of Cardiology in collaboration with the Heart Failure National Societies/Working Groups. European Journal of Heart Failure, 2013, 15, 947-959.	7.1	75

#	ARTICLE	IF	CITATIONS
289	Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF. <i>European Heart Journal</i> , 2013, 34, 3128-3136.	2.2	56
290	Guía de práctica clínica sobre el tratamiento de las valvulopatías (versión 2012). <i>Revista Española De Cardiología</i> , 2013, 66, 131.e1-131.e42.	1.2	2
291	Documento de consenso de expertos. Tercera definición universal del infarto de miocardio. <i>Revista Española De Cardiología</i> , 2013, 66, 132.e1-132.e15.	1.2	18
292	Effect of Serelaxin on Cardiac, Renal, and Hepatic Biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) Development Program. <i>Journal of the American College of Cardiology</i> , 2013, 61, 196-206.	2.8	397
293	Prognostic value of high sensitivity troponin T in patients with acutely decompensated heart failure and non-detectable conventional troponin T levels. <i>International Journal of Cardiology</i> , 2013, 168, 3609-3612.	1.7	34
294	Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. <i>Lancet</i> , 2013, 381, 29-39.	13.7	810
295	Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. <i>European Heart Journal</i> , 2013, 34, 2453-2463.	2.2	419
296	Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2013, 15, 1173-1184.	7.1	533
297	Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. <i>European Journal of Heart Failure</i> , 2013, 15, 1401-1411.	7.1	119
298	Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial. <i>European Journal of Heart Failure</i> , 2013, 15, 1267-1276.	7.1	130
299	EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). <i>European Journal of Heart Failure</i> , 2013, 15, 808-817.	7.1	645
300	Third Universal Definition of Myocardial Infarction. <i>Circulation</i> , 2012, 126, 2020-2035.	1.6	2,722
301	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. <i>European Heart Journal</i> , 2012, 33, 1787-1847.	2.2	5,233
302	Central sleep apnea treatment in heart failure: are we counting chickens before they are hatched? Expert Review of Cardiovascular Therapy, 2012, 10, 275-278.	1.5	2
303	Beyond the cardiorenal anaemia syndrome: recognizing the role of iron deficiency. <i>European Journal of Heart Failure</i> , 2012, 14, 882-886.	7.1	71
304	Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes. <i>European Journal of Heart Failure</i> , 2012, 14, 1056-1066.	7.1	105
305	Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm. A Joint Consensus Document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis. <i>European Journal of Heart Failure</i> , 2012, 14, 681-695.	7.1	71
306	Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease. <i>European Journal of Heart Failure</i> , 2012, 14, 668-675.	7.1	72

#	ARTICLE	IF	CITATIONS
307	Third universal definition of myocardial infarction. European Heart Journal, 2012, 33, 2551-2567.	2.2	2,447
308	Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm. Thrombosis and Haemostasis, 2012, 108, 1009-1022.	3.4	65
309	Recomendações da ESC para o tratamento da cardiopatia congénita no adulto (nova versão de 2010). Revista Portuguesa De Cardiologia, 2012, 31, 541.e1-541.e53.	0.5	0
310	Guidelines on the management of valvular heart disease (version 2012). European Heart Journal, 2012, 33, 2451-2496.	2.2	3,465
311	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. European Journal of Heart Failure, 2012, 14, 803-869.	7.1	2,307
312	Troponin elevation in patients with heart failure: on behalf of the third Universal Definition of Myocardial Infarction Global Task Force: Heart Failure Section. European Heart Journal, 2012, 33, 2265-2271.	2.2	256
313	Guidelines on the management of valvular heart disease (version 2012). European Journal of Cardio-thoracic Surgery, 2012, 42, S1-S44.	1.4	1,313
314	Design of the RELAXin in Acute Heart Failure Study. American Heart Journal, 2012, 163, 149-155.e1.	2.7	60
315	Levosimendan: Molecular mechanisms and clinical implications. International Journal of Cardiology, 2012, 159, 82-87.	1.7	256
316	Third Universal Definition of Myocardial Infarction. Journal of the American College of Cardiology, 2012, 60, 1581-1598.	2.8	2,558
317	Guía de práctica clínica de la ESC sobre diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica 2012. Revista Espanola De Cardiologia, 2012, 65, 938.e1-938.e59.	1.2	31
318	Modeling and simulation of right ventricular volume measurement system during right heart catheterization. Journal of Medical Systems, 2012, 36, 615-620.	3.6	3
319	Iron Deficiency Predicts Impaired Exercise Capacity in Patients With Systolic Chronic Heart Failure. Journal of Cardiac Failure, 2011, 17, 899-906.	1.7	227
320	ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). European Heart Journal, 2011, 32, 1769-1818.	2.2	2,767
321	Pulmonary Congestion in Acute Heart Failure: From Hemodynamics to Lung Injury and Barrier Dysfunction. Revista Espanola De Cardiologia (English Ed ), 2011, 64, 735-738.	0.6	10
322	Istaroxime: Is the Remedy Better than the Disease?. Cardiovascular Drugs and Therapy, 2011, 25, 115-117.	2.6	2
323	Heart failure diagnosis and prognosis in the elderly: the proof of the pudding is in the eating. European Journal of Heart Failure, 2011, 13, 467-471.	7.1	31
324	Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. European Journal of Anaesthesiology, 2010, 27, 92-137.	1.7	263

#	ARTICLE	IF	CITATIONS
325	The impact of early standard therapy on dyspnoea in patients with acute heart failure: the URGENT-dyspnoea study. European Heart Journal, 2010, 31, 832-841.	2.2	159
326	2010 Focused Update of ESC Guidelines on device therapy in heart failure. European Journal of Heart Failure, 2010, 12, 1143-1153.	7.1	152
327	Dyspnoea and worsening heart failure in patients with acute heart failure: results from the PreaRELAXAHF study. European Journal of Heart Failure, 2010, 12, 1130-1139.	7.1	88
328	EURObservational Research Programme: The Heart Failure Pilot Survey (ESC-HF Pilot). European Journal of Heart Failure, 2010, 12, 1076-1084.	7.1	340
329	Iron deficiency: an ominous sign in patients with systolic chronic heart failure. European Heart Journal, 2010, 31, 1872-1880.	2.2	515
330	Acute Heart Failure Clinical Drug Development: From Planning to Proof of Activity to Phase III. Cardiology, 2010, 116, 292-301.	1.4	11
331	Assessing and grading congestion in acute heart failure: a scientific statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. European Journal of Heart Failure, 2010, 12, 423-433.	7.1	593
332	Plasma B-type natriuretic peptide reduction predicts long-term response to levosimendan therapy in acutely decompensated chronic heart failure. International Journal of Cardiology, 2010, 139, 75-79.	1.7	23
333	Functional Electrical Stimulation is More Effective in Severe Symptomatic Heart Failure Patients and Improves Their Adherence to Rehabilitation Programs. Journal of Cardiac Failure, 2010, 16, 244-249.	1.7	38
334	2010 Focused Update of ESC Guidelines on device therapy in heart failure. Europace, 2010, 12, 1526-1536.	1.7	297
335	Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal, 2010, 31, 2501-2555.	2.2	2,649
336	Guidelines for the management of atrial fibrillation. Europace, 2010, 12, 1360-1420.	1.7	1,360
337	Society of Chest Pain Centers recommendations for the evaluation and management of the observation stay acute heart failure patientâ€”part 1. Acute Cardiac Care, 2009, 11, 3-42.	0.2	43
338	Acute heart failure syndromes: Epidemiology, risk stratification and prognostic factors. Acute Cardiac Care, 2009, 11, 77-82.	0.2	6
339	Digoxin for the treatment of chronic and acute heart failure syndromes. Acute Cardiac Care, 2009, 11, 83-87.	0.2	21
340	Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2009, 11, 119-129.	7.1	281
341	Rationale and design of Ferinject® Assessment in patients with IRon deficiency and chronic Heart Failure (FAIRâ€”HF) study: a randomized, placeboâ€”controlled study of intravenous iron supplementation in patients with and without anaemia. European Journal of Heart Failure, 2009, 11, 1084-1091.	7.1	105
342	Hyponatremia in heart failure. Heart Failure Reviews, 2009, 14, 59-63.	3.9	54



#	ARTICLE	IF	CITATIONS
343	Reduction in Circulating Testosterone Relates to Exercise Capacity in Men With Chronic Heart Failure. <i>Journal of Cardiac Failure</i> , 2009, 15, 442-450.	1.7	87
344	The Rationale for an Acute Heart Failure Syndromes Clinical Trials Network. <i>Journal of Cardiac Failure</i> , 2009, 15, 467-474.	1.7	24
345	Acute Heart Failure Syndromes in Patients With Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2009, 53, 254-263.	2.8	124
346	Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency. <i>New England Journal of Medicine</i> , 2009, 361, 2436-2448.	27.0	1,633
347	Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. <i>European Heart Journal</i> , 2009, 30, 2769-2812.	2.2	735
348	Pharmacologic Stabilization and Management of Acute Heart Failure Syndromes in the Emergency Department. <i>Heart Failure Clinics</i> , 2009, 5, 43-54.	2.1	5
349	Vasopressin and vasopressin antagonists in heart failure and hyponatremia. <i>Current Heart Failure Reports</i> , 2008, 5, 91-96.	3.3	16
350	Guidelines on the diagnosis and management of acute pulmonary embolism. <i>European Heart Journal</i> , 2008, 29, 2276-2315.	2.2	2,645
351	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). <i>European Heart Journal</i> , 2008, 29, 2388-2442.	2.2	2,656
352	Management of Atrial Fibrillation in Patients With Heart Failure. <i>Journal of Cardiac Failure</i> , 2008, 14, 232-237.	1.7	27
353	Improvements in Signs and Symptoms During Hospitalization for Acute Heart Failure Follow Different Patterns and Depend on the Measurement Scales Used: An International, Prospective Registry to Evaluate the Evolution of Measures of Disease Severity in Acute Heart Failure (MEASURE-AHF). <i>Journal of Cardiac Failure</i> , 2008, 14, 777-784.	1.7	43
354	Vasopressin Antagonists for the Treatment of Acute Decompensated Heart Failure: When, for Whom, for How Long, and on What Standard Therapy?. <i>Journal of Cardiac Failure</i> , 2008, 14, 648-650.	1.7	6
355	Effects of levosimendan on flow-mediated vasodilation and soluble adhesion molecules in patients with advanced chronic heart failure. <i>Atherosclerosis</i> , 2008, 197, 278-282.	0.8	70
356	Novel biologic mechanisms of levosimendan and its effect on the failing heart. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 1143-1150.	4.1	38
357	A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach. <i>European Heart Journal</i> , 2008, 29, 816-824.	2.2	131
358	Acute Heart Failure Treatment. <i>Critical Pathways in Cardiology</i> , 2008, 7, 103-110.	0.5	2
359	Overview of emerging pharmacologic agents for acute heart failure syndromes. <i>European Journal of Heart Failure</i> , 2008, 10, 201-213.	7.1	39
360	Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. <i>European Heart Journal</i> , 2008, 29, 2909-2945.	2.2	2,128

#	ARTICLE	IF	CITATIONS
361	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. European Journal of Heart Failure, 2008, 10, 933-989.	7.1	1,893
362	Society of Chest Pain Centers Recommendations for the Evaluation and Management of the Observation Stay Acute Heart Failure Patient. Critical Pathways in Cardiology, 2008, 7, 83-121.	0.5	38
363	Practical recommendations for prehospital and early in-hospital management of patients presenting with acute heart failure syndromes. Critical Care Medicine, 2008, 36, S129-S139.	0.9	240
364	Effects of levosimendan on coronary artery flow and cardiac performance in patients with advanced heart failure. European Journal of Heart Failure, 2007, 9, 1172-1177.	7.1	32
365	Fourth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited) Tj ETQq1 1 0.284314 ngBT /Overl	2.8	4314
366	Universal Definition of Myocardial Infarction. Circulation, 2007, 116, 2634-2653.	1.6	2,755
367	Effects of Levosimendan on circulating markers of oxidative and nitrosative stress in patients with advanced heart failure. Atherosclerosis, 2007, 195, e210-e215.	0.8	54
368	Prognostic Value of Blood Urea Nitrogen in Patients Hospitalized With Worsening Heart Failure: Insights From the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) Study. Journal of Cardiac Failure, 2007, 13, 360-364.	1.7	138
369	Review of Current and Investigational Pharmacologic Agents for Acute Heart Failure Syndromes. American Journal of Cardiology, 2007, 99, S4-S23.	1.6	70
370	An introduction to acute heart failure syndromes: definition and classification. Heart Failure Reviews, 2007, 12, 87-90.	3.9	61
371	Epidemiology of acute heart failure syndromes. Heart Failure Reviews, 2007, 12, 91-95.	3.9	124
372	2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). European Heart Journal, 2006, 28, 1462-1536.	2.2	1,617
373	The second Euro Heart Survey on acute coronary syndromes: characteristics, treatment, and outcome of patients with ACS in Europe and the Mediterranean Basin in 2004. European Heart Journal, 2006, 27, 2285-2293.	2.2	496
374	Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. European Heart Journal, 2006, 28, 230-268.	2.2	1,802
375	Congestion in Acute Heart Failure Syndromes: An Essential Target of Evaluation and Treatment. American Journal of Medicine, 2006, 119, S3-S10.	1.5	339
376	Decompensated heart failure and cachexia: Is it time to legalize anabolics?. International Journal of Cardiology, 2006, 111, 185-186.	1.7	7
377	Prognosis and therapy approaches of cardiac cachexia. Current Opinion in Cardiology, 2006, 21, 229-233.	1.8	64
378	Effects of Levosimendan on Right Ventricular Function in Patients With Advanced Heart Failure. American Journal of Cardiology, 2006, 98, 1489-1492.	1.6	103

#	ARTICLE	IF	CITATIONS
379	Effects of Levosimendan on Markers of Left Ventricular Diastolic Function and Neurohormonal Activation in Patients With Advanced Heart Failure. American Journal of Cardiology, 2005, 96, 423-426.	1.6	94
380	Pathophysiologic Targets in the Early Phase of Acute Heart Failure Syndromes. American Journal of Cardiology, 2005, 96, 11-17.	1.6	255
381	Acute Heart Failure Syndromes. Circulation, 2005, 112, 3958-3968.	1.6	690
382	Levosimendan for the treatment of acute heart failure syndromes. Expert Opinion on Pharmacotherapy, 2005, 6, 2741-2751.	1.8	36
383	Regulation of apoptosis by angiotensin II in the heart and lungs (Review). International Journal of Molecular Medicine, 2001, 7, 273-80.	4.0	46